Generation Bio Co (GBIO) - News Archive

Showing 2 of 2 results.

Augmenting Treatment for T Cell-Driven Autoimmune Diseases Generation Bios Strategic Deployment of ctLNP Techno...

In a groundbreaking move within the biotechnology sector, Generation Bio Co. (Nasdaq: GBIO) is making strides in developing innovative therapeutics for T cell-driven autoimmune diseases. The company recently announced i...

Jan 6, 2025 • Major Pharmaceutical Preparations Industry Clinical Study The Generation Bio Generation Bio Stock Performanc

Innovations in Genetic Medicines: A Comprehensive View of Generation Bio's Preclinical Data on Immunoquiet DNA and Cell-Targeted Lipid Nanoparticle Platforms

The groundbreaking preclinical data on immunoquiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms unfolded at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting by the revoluti...

May 9, 2024 • Major Pharmaceutical Preparations Industry Clinical Study